University at Buffalo launches new incubator

November 5, 2012 by  

The University at Buffalo’s (UB) Niagara Medical Campus is about to have three new tenants.

Life sciences companies AccuTheranostics, Ceno Technologies, and AndroBioSys are all looking to leverage the research done at UB’s Clinical and Translational Research Center (CTRC) into marketable drugs.

In addition to housing researchers, the center is also a business incubator designed to foster cooperation and innovation between university faculty and private businesses concerned with turning biomedical discoveries into medicines.

Woody Maggard, an associate vice provost UB and manager of the incubator, said:

“We expect there will be a considerable number of discoveries coming out of the CTRC over time.”

The CTRC is located on the top floors of a structure built by University at Buffalo in collaboration with Kaleida Health. The building’s design was developed with an eye towards promoting interaction and engagement among all stakeholders concerned with advancements in the medical field.

Selection of the companies to be the first incubator tenants was done by a committee working under the auspices of the UB’s Office of Science, Technology Transfer, and Economic Outreach. According to the university, the space to be rented by the businesses includes offices and wet labs, plus access to free, specialized equipment and business consultation services.

In addition to the potential employment opportunities represented by start-up companies, area businesses that support new ventures, such as firms offering stationery printing or digital business cards , also welcome public-private entrepreneurial partnerships as represented by the innovative Clinical and Translational Research Center.

Of the three incubator tenants, AccuTheranostics is developing personalized chemotherapy treatments for cancer. AndroBioSys focuses on early detection and treatment of prostate cancer, while Ceno Technologies concentrates its activities on particle coatings with military, manufacturing, and drug applicability.

Comments